



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

04 December 2024
EMA/CAT/556207/2024
Human Medicines Division

Committee for Advanced Therapies (CAT)

Draft agenda for the meeting on 04-06 December 2024

Chair: Ilona Reischl; Vice-Chair: Kieran Breen

04 December 2024, 14:00 – 18:30, room 1C

05 December 2024, 09:00 – 18:30, room 1C

06 December 2024, 09:00 – 13:00, room 1C

Health and safety information

In accordance with the Agency's health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers

Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CAT meeting reports once the procedures are finalised.

Of note, this agenda is a working document primarily designed for CAT members and the work the Committee undertakes.

Note on access to documents

Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to on-going procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).



Table of contents

1.	Introduction	5
1.1.	Welcome and declarations of interest of members, alternates and experts.....	5
1.2.	Adoption of agenda	5
1.3.	Adoption of the minutes	5
2.	Evaluation of ATMPs	5
2.1.	Opinions	5
2.2.	Oral explanations	5
2.2.1.	Beremagene geperpavec - PRIME - Orphan - EMEA/H/C/006330	5
2.3.	Day 180 list of outstanding issues	5
2.4.	Day 120 list of questions	6
2.4.1.	Lifileucel - EMEA/H/C/004741	6
2.5.	Day 80 assessment reports	6
2.6.	Update on ongoing initial applications.....	6
2.7.	New applications	6
2.8.	Withdrawal of initial marketing authorisation application	6
2.9.	Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004	6
2.10.	GMP and GCP inspections requests.....	6
2.11.	Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008	6
2.11.1.	Alofisel - Darvadstrocel - Orphan - EMEA/H/C/004258/II/0051/G	6
2.11.2.	Casgevy - Exagamglogene autotemcel - Orphan - EMEA/H/C/005763/II/0009/G	7
2.11.3.	Ebvallo - Tabelecleucel - Orphan - EMEA/H/C/004577/II/0011/G	7
2.11.4.	Hemgenix - Etranacogene dezaparvovec - Orphan - EMEA/H/C/004827/II/0018.....	7
2.11.5.	Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0086/G	8
2.11.6.	Tecartus - Brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/II/0051	8
2.11.7.	Upstaza - Eladocogene exuparvovec - Orphan - EMEA/H/C/005352/II/0023/G	8
2.11.8.	Yescarta - Axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0077.....	8
2.11.9.	Zolgensma - Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0052	9
2.11.10.	Tecartus - Axicabtagene ciloleucel; Yescarta - Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2500.....	9
2.11.11.	Tecartus - Axicabtagene ciloleucel; Yescarta - Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2736.....	9
2.12.	Extension applications.....	9
2.13.	Other Post-Authorisation Activities	10
2.13.1.	Breyanzi - Lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/018.1.....	10
2.13.2.	CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/ANX/003.3	10

2.13.3.	Casgevvy - Exagamglogene autotemcel - Orphan - EMEA/H/C/005763/R/0006	10
2.13.4.	Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/S/0025	10
2.13.5.	Zolgensma - Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/LEG/024.1	10
2.14.	Companion diagnostics - initial consultation	11
2.15.	Companion diagnostics – Follow-up consultation	11
3.	Certification of ATMPs	11
3.1.	Opinion	11
3.2.	Day 60 Evaluation Reports	11
3.3.	New Applications	11
4.	Scientific Recommendation on Classification of ATMPs	11
4.1.	New requests – Appointment of CAT Coordinator	11
4.1.1.	mRNAs encoding IL-12 and IL-18	11
4.1.2.	BCMA targeting Chimeric Antigen Receptor expressing mRNA transfected autologous T cells	12
4.1.3.	Treatment of anaemia	12
4.1.4.	Autologous Tumor Infiltrating Lymphocytes (TILs)	12
4.2.	Day 30 ATMP scientific recommendation	12
4.2.1.	Autologous primary urothelial cells expanded	12
4.2.2.	Adeno-associated virus serotype 5 containing the human NR2E3 gene (AAV5-hNR2E3)	12
4.2.3.	CD70 CAR+, TCRαβ– viable cells	13
4.3.	Day 60 revised scientific recommendation (following list of questions)	13
4.4.	Finalisation of procedure	13
4.4.1.	Allogeneic CD19(4G7)CAR+_TCRαβ–_CD52+/- cells	13
4.4.2.	Autologous adult bone marrow-derived, non-expanded CD133+ haematopoietic stem cells	13
4.4.3.	Chimeric group B adenovirus from parental wildtype viruses Ad3 and Ad7 with attenuation in E3 region and no inserted sequences	13
4.5.	Follow-up and guidance	13
5.	Scientific Advice	13
5.1.	New requests - appointment of CAT Rapporteurs	14
5.1.1.	Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers	14
5.1.2.	Scientific advice procedures starting at the next SAWP meeting	14
5.2.	Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs	14
5.3.	Finalisation of D70 procedures – feedback from the discussion meeting	14
5.4.	Final Advice Letters for procedures finalised the previous month	14
6.	Pre-Authorisation Activities	14
6.1.	Paediatric investigation plans	14
6.2.	ITF briefing meetings in the field of ATMPs	14
6.3.	Priority Medicines (PRIME) – Eligibility requests	15

6.3.1.	Month 0 - Start of the procedure	15
6.3.2.	Month 1 – Discussion of eligibility	15
6.3.3.	Month 2 – Recommendation of eligibility.....	15
6.3.4.	Ongoing support.....	15

7.	Organisational, regulatory and methodological matters	15
-----------	--	-----------

7.1.	Mandate and organisation of the CAT	15
7.1.1.	CAT membership	15
7.1.2.	Vote by proxy	15
7.1.3.	CAT Strategic Review & Learning meeting (SRLM) under the Hungarian presidency – 19-20 November 2024.....	15
7.1.4.	CAT deadlines around the end of year holiday period	16
7.2.	Coordination with EMA Scientific Committees.....	16
7.3.	Coordination with EMA Working Parties/Working Groups/Drafting Groups	16
7.4.	Cooperation with the EU regulatory network.....	16
7.5.	Cooperation with international regulators.....	16
7.5.1.	EMA/FDA Collaborations / Liaison Officials Programme	16
7.5.2.	ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan).....	16
7.6.	CAT work plan	16
7.6.1.	CAT work plan 2025.....	16
7.6.2.	Guideline on quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials	16
7.7.	Action: for discussion Planning and reporting	17
7.8.	Others	17
7.8.1.	Clinical study data pilot	17
7.8.2.	Unauthorised Dendritic cell therapies	17

8.	Any other business	17
-----------	---------------------------	-----------

9.	Explanatory notes	18
-----------	--------------------------	-----------

1. Introduction

1.1. Welcome and declarations of interest of members, alternates and experts

Pre-meeting list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CAT plenary session to be held 04-06 December 2024. See December 2024 CAT minutes (to be published post January 2025 CAT meeting).

1.2. Adoption of agenda

CAT agenda for 04-06 December 2024 meeting

1.3. Adoption of the minutes

CAT minutes for 06-09 November 2024 meeting

2. Evaluation of ATMPs

2.1. Opinions

No items

2.2. Oral explanations

2.2.1. Beremagene geperpavec - PRIME - Orphan - EMEA/H/C/006330

Krystal Biotech Netherlands B.V.; Treatment of patients from birth with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene

Scope: List of outstanding issues

Action: for discussion

List of outstanding issues adopted on 11.10.2024. List of questions adopted on 15.03.2024.

2.3. Day 180 list of outstanding issues

No items

2.4. Day 120 list of questions

2.4.1. Lifileucel - EMEA/H/C/004741

Treatment of unresectable or metastatic melanoma

Scope: Day 120 list of questions

Action: for adoption

2.5. Day 80 assessment reports

No items

2.6. Update on ongoing initial applications

No items

2.7. New applications

No items

2.8. Withdrawal of initial marketing authorisation application

2.9. Re-examination of initial application procedures under Article 9(2) of Regulation No. 726/2004

No items

2.10. GMP and GCP inspections requests

No items

2.11. Type II variations and variations of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

2.11.1. Alofisel - Darvadstrocel - Orphan - EMEA/H/C/004258/II/0051/G

Takeda Pharma A/S

Rapporteur: Maria Luttgen; PRAC Rapporteur: Gabriele Maurer

Scope: Safety

A grouped application comprised of 4 Type II Variations, as follows:

(C.I.4): Update of sections 4.8 and 5.1 of the SmPC in order to update the safety information, based on pooled safety data from the two phase 3 controlled studies (ADMIRE-CD & ADMIRE-CD II) and to update efficacy information based on final results from study

ADMIRE-CD II, listed as an obligation in the Annex II. ADMIRE-CD II (Cx601-0303) is a Phase III randomised double blind, placebo-controlled study to assess efficacy and safety of Cx601, adult allogeneic expanded adipose-derived stem cells (eASC) for the treatment of complex perianal fistula(s) in patients with Crohn's disease. The Annex II is updated accordingly. In addition, the MAH took the opportunity to introduce minor changes to the PI, including to section 4.2 of the SmPC and to the Package Leaflet.

3 x (C.I.13): Submission of interim results from studies Darvadstrocel-3003 and Alofisel-5003 (INSPIRE) and final results from study Darvadstrocel-3002 to support the benefit-risk assessment of darvadstrocel based on all new available clinical data.

The RMP version 8.0 has also been submitted.

Action: for adoption

Request for Supplementary Information adopted on 19.07.2024.

2.11.2. Casgevy - Exagamglogene autotemcel - Orphan - EMEA/H/C/005763/II/0009/G

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus

Scope: Quality

Action: for adoption

2.11.3. Ebvallo - Tabelecleucel - Orphan - EMEA/H/C/004577/II/0011/G

Pierre Fabre Medicament

Rapporteur: Egbert Flory

Scope: Quality

Action: for adoption

Request for Supplementary Information adopted on 08.11.2024, 13.09.2024.

2.11.4. Hemgenix - Etranacogene dezaparvovec - Orphan - EMEA/H/C/004827/II/0018

CSL Behring GmbH

Rapporteur: Silke Dorner

Scope: Clinical, opinion

Update of sections 4.4 and 5.1 of the SmPC in order to reflect a modified 9-point anti-AAV5 Neutralising Antibody (NAb) assay. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet and bring the PI in line with the QRD version 10.4.

Action: for adoption

Request for Supplementary Information adopted on 08.11.2024.

2.11.5. Kymriah - Tisagenlecleucel - Orphan - EMEA/H/C/004090/II/0086/G

Novartis Europharm Limited

Rapporteur: Rune Kjekken

Scope: Safety

A grouped application consisting of:

C.I.4: Update of section 4.4 of the SmPC in order to amend existing warnings on cytokine release syndrome based on literature.

C.I.4: Update of section 4.4 of the SmPC in order to amend existing warnings on neurological adverse reaction based on literature. The Package Leaflet is updated accordingly.

C.I.4: Update of section 4.4 of the SmPC in order to amend existing warnings on hypersensitivity reactions based on post marketing data and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to implement editorial changes to the PI.

Action: for adoption

Request for Supplementary Information adopted on 11.10.2024.

2.11.6. Tecartus - Brexucabtagene autoleucel - Orphan - EMEA/H/C/005102/II/0051

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Bianca Mulder

Scope: Clinical, RSI

Submission of the final study report for the non-interventional study KT-EU-472-5966 titled "Quantitative Testing of Health Care Professional Knowledge About Tecartus Risk Minimisation Measures" listed as a category 3 study in the RMP (PRAC-led procedure)

Action: for adoption

2.11.7. Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/II/0023/G

PTC Therapeutics International Limited

Rapporteur: Joseph DeCoursey

Scope: Quality, opinion

Action: for adoption

Request for Supplementary Information adopted on 11.10.2024.

2.11.8. Yescarta - Axicabtagene ciloleucel - Orphan - EMEA/H/C/004480/II/0077

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus

Scope: Quality, opinion

Action: for adoption

Request for Supplementary Information adopted on 19.07.2024.

2.11.9. [Zolgensma - Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/II/0052](#)

Novartis Europharm Limited

Rapporteur: Emmely de Vries

Scope: Clinical

Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and vector shedding data following request in procedure EMA/H/C/004750/P46/022 and based on data from study COAV101A12306. In addition, a reference to section 5.2 is added to section 4.4, as requested in final Assessment report of procedure EMA/H/C/004750/P46/022.

Action: for adoption

Request for Supplementary Information adopted on 11.10.2024.

2.11.10. [Tecartus - Axicabtagene ciloleucel; Yescarta - Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2500](#)

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghus

Scope: Quality, opinion

Action: for adoption

Request for Supplementary Information adopted on 11.10.2024, 24.05.2024, 16.02.2024.

2.11.11. [Tecartus - Axicabtagene ciloleucel; Yescarta - Brexucabtagene autoleucel - Orphan - EMEA/H/C/WS2736](#)

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghus

Scope: Quality, Request for Supplementary Information

Action: for adoption

Request for Supplementary Information adopted on 13.09.2024.

2.12. **Extension applications**

No items

2.13. Other Post-Authorisation Activities

2.13.1. Breyanzi - Lisocabtagene maraleucel / lisocabtagene maraleucel - EMEA/H/C/004731/REC/018.1

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Concetta Quintarelli

Scope: Quality

Action: for adoption

2.13.2. CARVYKTI - Ciltacabtagene autoleucel - Orphan - EMEA/H/C/005095/ANX/003.3

Janssen-Cilag International NV

Rapporteur: Jan Mueller-Berghaus

Scope: Pharmacovigilance

Second Interim Report / PASS Study 68284528MMY4004

Title: An Observational Post-authorisation Safety Study to Evaluate the Safety of Multiple Myeloma Patients Treated with Ciltacabtagene Autoleucel.
(From initial MAA)

Action: for adoption

2.13.3. Casgevy - Exagamglogene autotemcel - Orphan - EMEA/H/C/005763/R/0006

Vertex Pharmaceuticals (Ireland) Limited

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Heli Suila, PRAC Rapporteur: Bianca Mulder

Scope: 1 year Renewal of Marketing Authorisation, opinion

Action: for adoption

Request for Supplementary Information adopted on 11.10.2024.

2.13.4. Upstaza - Eladocagene exuparvovec - Orphan - EMEA/H/C/005352/S/0025

PTC Therapeutics International Limited

Rapporteur: Joseph DeCoursey, Co-Rapporteur: Maria Luttgen, PRAC Rapporteur: Gabriele Maurer

Scope: Annual Re-assessment

Action: for adoption

2.13.5. Zolgensma - Onasemnogene abeparvovec - Orphan - EMEA/H/C/004750/LEG/024.1

Novartis Europharm Limited

Rapporteur: Emmely de Vries

Scope: Non-clinical

MAH's response to LEG 024 [from PSUSA-00010848-202305: Study reports for 2170026 & 222018] RSI as adopted in July 2024.

Study no. 2170026 (OAV101: Single Dose Intravenous or Intracerebroventricular Germline Transduction and Integration Study in Neonatal FVB/NCrl Mice with up to a 24-Week Evaluation Period).

Study no. 2220183: AAV Vector expression in cynomolgus macaque gonadal tissue of scAAV9-CB-GFP and scAAV9-CB-mCherry 28 days after administration, Molecular Localization Report.

Action: for adoption

2.14. Companion diagnostics - initial consultation

No items

2.15. Companion diagnostics – Follow-up consultation

No items

3. Certification of ATMPs

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

3.1. Opinion

No items

3.2. Day 60 Evaluation Reports

No items

3.3. New Applications

4. Scientific Recommendation on Classification of ATMPs

4.1. New requests – Appointment of CAT Coordinator

4.1.1. mRNAs encoding IL-12 and IL-18

Treatment of gastric cancer

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.2. BCMA targeting Chimeric Antigen Receptor expressing mRNA transfected autologous T cells

Treatment of generalised myasthenia gravis

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

Lab grown red blood cells

4.1.3. Treatment of anaemia

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.1.4. Autologous Tumor Infiltrating Lymphocytes (TILs)

Treatment of adult patients with advanced or 2/4 metastatic solid tumors who have not responded to standard therapies (chemotherapy, radiation therapy, molecule-targeted therapy) or are ineligible for alternative treatment options or in associated treatment with chemotherapy in multimodal therapy

Scope: Appointment of CAT Coordinator and adoption of timetable

Action: for adoption

4.2. Day 30 ATMP scientific recommendation

4.2.1. Autologous primary urothelial cells expanded

Treatment of cystoplasty/orthotopic neobladder

Scope: ATMP scientific recommendation

Action: for adoption

4.2.2. Adeno-associated virus serotype 5 containing the human NR2E3 gene (AAV5-hNR2E3)

Treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy, specifically retinitis pigmentosa or Leber congenital amaurosis, and who have sufficient viable retinal cells

Scope: ATMP scientific recommendation

Action: for adoption

4.2.3. CD70 CAR+, TCRαβ– viable cells

Treatment of renal cell carcinoma

Scope: ATMP scientific recommendation

Action: for adoption

4.3. Day 60 revised scientific recommendation (following list of questions)

No items

4.4. Finalisation of procedure

4.4.1. Allogeneic CD19(4G7)CAR+_TCRαβ–_CD52+/- cells

Treatment of CD19-expressing hematologic malignancies

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

4.4.2. Autologous adult bone marrow-derived, non-expanded CD133+ haematopoietic stem cells

Treatment of Asherman's syndrome

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

4.4.3. Chimeric group B adenovirus from parental wildtype viruses Ad3 and Ad7 with attenuation in E3 region and no inserted sequences

Treatment of ovarian cancer

Scope: European Commission raised no comments. ATMP scientific recommendation

Action: for adoption

4.5. Follow-up and guidance

No items

5. Scientific Advice

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

5.1. New requests - appointment of CAT Rapporteurs

5.1.1. Ongoing scientific advice procedures - Appointment of CAT Peer Reviewers

Timetable:

- Start of procedure at SAWP:	25-28.11.2024
- Appointment of CAT Peer Reviewers:	04-06.12.2024
- SAWP first reports:	06.01.2025
- CAT Peer Reviewer comments (NC/C):	10.01.2025
- CAT Peer Reviewer comments (Q):	15.01.2025
- Discussion at SAWP:	13-16.01.2025
- Discussion at CAT and feedback to SAWP:	22-24.01.2025

5.1.2. Scientific advice procedures starting at the next SAWP meeting

Timetable:

- Start of procedure at SAWP:	13-16.01.2025
- Appointment of CAT Peer Reviewers:	22-24.01.2025
- SAWP first reports:	03.02.2025
- CAT Peer Reviewer comments (NC/C):	07.02.2025
- CAT Peer Reviewer comments (Q):	12.02.2025
- Discussion at SAWP:	10-13.02.2025
- Discussion at CAT and feedback to SAWP:	19-21.02.2025

5.2. Procedures discussed at SAWP – 1st reports, D40 JRs, LoIs

5.3. Finalisation of D70 procedures – feedback from the discussion meeting

5.4. Final Advice Letters for procedures finalised the previous month

6. Pre-Authorisation Activities

Information related to this section cannot be released at the present time as it is deemed to contain commercially confidential information.

6.1. Paediatric investigation plans

No items

6.2. ITF briefing meetings in the field of ATMPs

No items

6.3. Priority Medicines (PRIME) – Eligibility requests

6.3.1. Month 0 - Start of the procedure

Timetable for assessment:	
Procedure start:	25-28.11.2024
SAWP recommendation:	16.01.2025
CAT recommendation:	24.01.2025
CHMP adoption of report and final recommendation:	30.01.2025

6.3.2. Month 1 – Discussion of eligibility

6.3.3. Month 2 – Recommendation of eligibility

6.3.4. Ongoing support

No items

7. Organisational, regulatory and methodological matters

7.1. Mandate and organisation of the CAT

7.1.1. CAT membership

EMA: Patrick Celis

Action: for information

7.1.2. Vote by proxy

Action: for information

7.1.3. CAT Strategic Review & Learning meeting (SRLM) under the Hungarian presidency – 19-20 November 2024

CAT: Andras Donaszi-Ivanov, Viola Bardóczy

Scope: Feedback from the meeting

Action: for information

7.1.4. CAT deadlines around the end of year holiday period

CAT: Emmely de Vries, Tineke van den Hoorn

Action: for information

Note: topic raised in September by delegates from Netherlands in CAT, PRAC and CHMP

7.2. Coordination with EMA Scientific Committees

No items

7.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

No items

7.4. Cooperation with the EU regulatory network

No items

7.5. Cooperation with international regulators

7.5.1. EMA/FDA Collaborations / Liaison Officials Programme

Scope: Awareness of EMA/FDA collaboration and Liaison Program

Action: for information

7.5.2. ATMP cluster teleconference with US-FDA, Health Canada and PMDA (Japan)

CAT: Ilona Reischl

Scope: Draft agenda of the teleconference of 12.12.2024

Action: for discussion

7.6. CAT work plan

7.6.1. CAT work plan 2025

CAT: Ilona Reischl

Scope: CAT work plan 2025

Action: for appointment of CAT contributors to the workplan topics

7.6.2. Guideline on quality, non-clinical and clinical requirements for investigational ATMPs in clinical trials

CAT: Ilona Reischl

Scope: Draft guideline, updated following comments from GCG, CAT and BWP members

Action: for adoption

7.7. Action: for discussion Planning and reporting

No items

7.8. Others

7.8.1. Clinical study data pilot

Scope: EMA has decided to extend the pilot's duration. As a result, pilot participation requests from pharmaceutical industry will continue to be accepted until further notice

Action: for information

7.8.2. Unauthorised Dendritic cell therapies

CAT: Joseph De Courcey, Ilona Reischl

Scope: Exchange on national investigations of the involved companies

Action: for discussion

8. Any other business

No items

Date of next CAT meeting:

22-24 January 2025

9. Explanatory notes

The Notes give a brief explanation of relevant agenda items and should be read in conjunction with the agenda.

For a list of acronyms and abbreviations, see:

[List of abbreviations used in EMA human medicines scientific committees and CMDh documents, and in relation to EMA's regulatory activities](#)


Evaluation of ATMPs (section 2)

This section lists applications for marketing authorisations of new Advanced Therapy Medicinal Products (ATMPs) that are to be discussed by the Committee. It also lists Post-authorisation activities (section 2.11-2.13) and any ATMP related inspection requests (section 2.14).

New applications (sections 2.1. to 2.9.)

Section 2.1 is for ATMPs nearing the end of the evaluation and for which the CAT is expected to adopt a draft **opinion** at this meeting on whether marketing authorisation should be granted. Once adopted, the CAT opinion is transmitted to the CHMP for final adoption. The CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU. More information on the evaluation of ATMPs can be found [here](#).

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:



The assessment of an application for a new medicine takes up to 210 'active' days. This active evaluation time is interrupted by at least one 'clock-stop' during which time the applicant prepares the answers to questions from the CAT. The clock stop happens after day 120 and may also happen after day 180, when the CAT has adopted respectively a **Day 120 list of questions** (section 2.4) or a List of outstanding issues to be addressed by the company, which is listed in the agenda under sections 2.7 (**Ongoing evaluation procedures** (section 2.3)). Section 2.6 also includes the CAT discussions at any other timepoint of the evaluation procedure of new applications.

Oral explanation (section 2.2.)

Prior to adoption of the CAT opinion, marketing authorisation applicants are normally invited to the CAT plenary meeting to address questions raised by the Committee.

Oral explanations normally relate to ongoing applications, but they can also relate to any other issue for which the CAT would like to discuss with company representatives in person.

New applications (section 2.7.)

In this section, information is included on upcoming marketing authorisation applications for ATMPs, as well as information on appointment of Rapporteurs for new ATMP applications.

Withdrawal of applications (section 2.8.)

This section includes information on marketing authorisation applications that are withdrawn by the applicant. Applicants may decide to withdraw applications at any stage during the assessment and a CAT opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 2.9.)

This section lists applications for new marketing authorisation for ATMPs for which the applicant has requested a re-examination of the opinion previously issued by the CHMP. Similar to the initial evaluation of a marketing authorisation of an ATMP, CAT will adopt a draft re-examination opinion, which is transmitted to the CHMP for final adoption.

GMP and GCP Inspections Issues (section 2.14.)

This section lists inspections that are undertaken for ATMPs. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Post-authorisation activities (section 2.11-2.13.)

Section 2.11 lists type II variations, including extension of indication applications and re-examination procedures for type II variations for which the applicant has requested re-examination of the opinion previously issued by the CHMP. Section 2.12 list extension application according to Annex I of Reg. 1234/2008 and section 2.13 includes all other post-authorisation activities concerning authorised ATMPs that are not covered elsewhere in the agenda such as post-authorisation measures, annual reassessments, 5-year renewals, supply shortages, qualify defects. Issues that have been discussed at the previous meeting of the PRAC, the EMA's committee responsible for evaluating and monitoring safety issues for medicines, will also be included here.

Companion diagnostics (section 2.14-2.15)

This section lists applications for initial and follow-on consultation of companion diagnostics.

Certification of ATMPs (section 3)

This section includes the scientific evaluation by the CAT of quality and non-clinical data that small and medium-sized enterprises have generated at any stage of the ATMP development process. More information on the ATMP certification procedure can be found [here](#).

Scientific Recommendation on Classification of ATMPs (Section 4)

This section includes the scientific recommendation by the CAT on whether medicines based on genes, cells or tissues meet the scientific criteria that define ATMPs. More information on the ATMP classification procedure, including the outcomes of finalised classifications, can be found [here](#).

Scientific Advice (section 5)

This section includes all scientific advice given to companies during the development of an ATMP. Information related to the number of ATMP related scientific advices discussed by CAT can be found in the CAT Monthly reports. Further information on SAWP can be found [here](#).

Pre-Authorisation (section 6)

Paediatric Investigation Plan (PIP)

This section includes the discussion of an ATMP before a formal application for marketing authorisation is submitted. These cases refer for example to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation: in case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

CAT contributes to the evaluation of a Paediatric Investigation Plan (PIPs) for ATMPs by the Paediatric Committee. These PIPs are included in this section of the Agenda.

ITF Briefing meeting in the field of ATMPs

This section refers to briefing meetings of the Innovation Task Force and International co-operations activities of the CAT

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes of meetings with applicants developing ATMPs and of other ITF meetings of interest to the CAT are included in this section of the agenda. Further information on the ITF can be found [here](#).

Priority Medicines (PRIME)

This section includes the new requests for eligibility to PRIME for ATMPs under development, the discussions in CAT of these eligibility requests and the final recommendations for eligibility of ATMPs adopted by CHMP.

CAT will appoint one of its members as the CAT sponsor for each new ATMP eligibility request who will lead the CAT discussion based on the recommendation from the SAWP.

Organisational, regulatory and methodological matters (section 7)

This section includes topics related to regulatory and procedural guidance, CAT workplan, CAT meeting organisation (including CAT membership), planning and reporting, co-ordination with other committees, working parties and scientific advisory groups.

Furthermore, this section refers to the activities of the CAT drafting groups developing scientific guidelines for gene therapy medicinal products and for cell-based medicinal products, cooperation within the EU regulatory network and international regulators as well as direct interaction with interested parties. It also includes topics of scientific interest for the Committee that are not directly related to the work of the CAT drafting groups or CAT associated working parties.

Any other business (section 8)

This section is populated with miscellaneous topics not suitable under the previous headings.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/